CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc. (CNSP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cnsp · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for CNS Pharmaceuticals, Inc. (CNSP) measures how much investors pay for each dollar of the company's trailing earnings. CNSP's current PE ratio of N/A is calculated by dividing its stock price of $4.89 by its TTM earnings per share of -$24.38.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
CNS Pharmaceuticals, Inc.You CNSP | $3M | N/A | — | -$24.38 |
 Clearmind Medicine Inc. CMND | $4M | N/A | — | -$3.03 |
 Ensysce Biosciences, Inc. ENSC | $2M | N/A | — | -$3.98 |
 GRI Bio, Inc. GRI | $0M | N/A | — | -$121.80 |
 Pasithea Therapeutics Corp. KTTA | $4M | N/A | — | -$2.91 |
 NLS Pharmaceutics AG NLSP | $1M | N/A | — | -$26.31 |
 Oragenics, Inc. OGEN | $3M | N/A | — | -$4.56 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-35.75 | — | |
2024-12-31 FY2024 | — | $-466.45 | — | |
2023-12-31 FY2023 | — | $-150114.40 | — | |
2022-12-31 FY2022 | — | $-336499.65 | — | |
2021-12-31 FY2021 | — | $-495025.46 | — | |
2020-12-31 FY2020 | — | $-512207.13 | — | |
2019-12-31 FY2019 | — | $-212124.03 | — | |
2018-12-31 FY2018 | — | $-404414.25 | — | |
2017-12-31 FY2017 | — | $-28803.37 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for CNS Pharmaceuticals, Inc. (CNSP) measures how much investors pay for each dollar of the company's trailing earnings. CNSP's current PE ratio of N/A is calculated by dividing its stock price of $4.89 by its TTM earnings per share of -$24.38.
Frequently asked questions
CNSP pe ratio · 6 questionsCNSP's current PE ratio is N/A as of 2026-06-08, based on a stock price of $4.89 and TTM EPS of -$24.38. Data sourced from Financial Modeling Prep via CNSP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · CNS Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08